Company Overview and News
Monthly Paying (MoPay) dividend equities make dividend payouts to shareholders twelve times a year instead once, twice, or four times.
CCAOF EBGUF FFN OSP.PR.A CBL NAF.UN AD ALARF CRIUF BNEFF CHW.DB SOT.UN CJR.B CHW MR.UN AHOTF OSP CNDCF BK CHWWF CGIFF BNE LCS CJREF LCS.PR.A FNCSF
Razor Energy is an oil-weighted energy producer that has increased its production significantly since 2017 while maintaining a strong balance sheet with leverage being well below 2 times.
BTE PGH CJ CRLFF CPG WCP YGR BNEFF VET SGY ZPTAF RRENF YGRAF RRX QTEYF GXOCF QEC TNEYF GENGF ATU CPG BNE RZREF GXO VET IPOOF GXE BTE SPGYF
CALGARY, Alberta, May 15, 2018 (GLOBE NEWSWIRE) -- Bonterra Energy Corp. (www.bonterraenergy.com) (TSX:BNE) announced that at its annual general meeting of shareholders held on May 15, 2018, a total of 17,332,310 shares, representing 52.03% of common shares outstanding, were represented in person or by proxy. Shareholders approved all resolutions listed in the management information circular dated April 3, 2018, including the election of each of the five nominees proposed as directors.
CALGARY, Alberta, April 02, 2018 (GLOBE NEWSWIRE) -- Bonterra Energy Corp. (www.bonterraenergy.com) (TSX:BNE) (“Bonterra” or the “Company”) announces that the March 2018 monthly cash dividend will be $0.10 per share and will be paid on April 30th, 2018. The record date for the dividend is April 16th, 2018 and the ex-dividend date is April 13th, 2018. The dividend is paid monthly and is subject to commodity prices and production levels.
Contents: 1. US/CDN Stocks @6.5%+ yield (125) 2. Stocks by price upside (30); 3. Closed-End Investment Companies, Exchange-Traded Funds & Notes (CEICs/ETFs/ETNs) @6.5%+ yield (70).
FNNCF CCAOF CBL AD CRIUF ALARF BNEFF ORC SOT.UN CJR.B ECC DGS.PR.A ECCZ AGNC AHOTF ECCY DGS DVSPF ECCB BNE CJREF ECCA GNL GNL.PRA
2018-06-22 - Asif
Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...
2018-06-22 - Asif
Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...
2018-06-18 - Asif
Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...
Silicon Investor Message Boards
This table lists all message boards related to TSX:BNE / Bonterra Energy Corp on message board site Silicon Investor.